Stock·NYSE·Healthcare
Hims & Hers Health, Inc. (HIMS)
- Market cap
- $6.55B
- Dividend yield
- 0.00%
- Street target
- $31.00median of 15 analysts
- 52-week range
- $13.74 $52.41
The short version
Where HIMS stands today, in four lines, and what CleaRank Financial AI makes of it.
HIMS at a glance
Hims & Hers Health, Inc. (HIMS): Hold, 45/100 on CleaRank's AI score.
- Trend Mixed: the price is above its 200-day but below its 50-day moving average ($27.27 and $29.32).
- Earnings HIMS beat estimates in 3 of its last 6 quarters, yet fell the next day after 2 of those beats.
- Insiders Insiders sold $154.9M and bought $1.2M over the last 18 months.
Figures as of October 17, 2026.
CleaRank Financial AI
CleaRank rates Hims & Hers Health, Inc. (HIMS) as Hold with a model score of 45/100.
The biggest boost comes from revenue growth of 38.20%, which runs 30.1 percentage points ahead of the sector median. The biggest drag is valuation, as the company has no meaningful P/E because it lost money. HIMS trades 4.27% below its 50-day average of $29.32 yet 2.95% above its 200-day average of $27.27, so the trend reads mixed. The price fell 52.54% across the past year.
Only on CleaRank
Figures we compute ourselves from HIMS's own price, earnings and insider-filing history. Tap one to see it in context.
Price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
2/4Price above its 50-day average ›
The price of $28.07 is 4.3% below the 50-day simple moving average of $29.32.Price above its 200-day average ›
The price is 2.9% above the 200-day simple moving average of $27.27.50-day average above the 200-day ›
The 50-day average ($29.32) is 7.5% above the 200-day average ($27.27), the arrangement of a rising longer-term trend.In the upper half of its 52-week range ›
The price sits at 37% of its 52-week range, between $13.74 and $52.41.
HIMS share price
Pick a period: each tab shows how far HIMS has moved over it, to the last close.
Today's trading
Where HIMS sits inside today's range and its 52-week range.
Fundamentals
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
1/3P/S below the sector median ›
The price-to-sales ratio of 2.51 is 26.2% below the sector median of 3.4.Profitable over the last 12 months ›
Net income over the last 12 months was $-142.0M on revenue of $2.6B, a net margin of -5.5%.Beat estimates in most recent reports ›
HIMS beat the EPS estimate in 3 of its last 6 reports.
Key statistics
The headline figures for HIMS.
As of October 17, 2026, HIMS trades at $28.07, with a market value of $6.55B and no P/E ratio (its trailing earnings are negative).
What the numbers say
CleaRank Financial AI's reading of HIMS's valuation, growth and risks.
HIMS has no meaningful P/E, since the company lost money over the last 12 months, so earnings cannot anchor its value. Sales tell a different story: its P/S of 2.51 is 26.2% below the sector median of 3.4.
Hims & Hers Health is losing money. Its net margin is -5.51%, its operating margin is -12.75%, and its return on equity of -32.03% sits below the sector median of 7.3%. Revenue expanded 38.20% over the latest year, a pace 30.1 percentage points ahead of the Healthcare median of 8.1%. Debt-to-equity stands at 4.77.
HIMS reported -$0.37 a share in its latest earnings report, dated August 10, 2026, well under the -$0.05 analysts had expected. That shortfall works out to 640.00% below the estimate. The stock dropped 3.97% in the following session.
HIMS has beaten the EPS estimate in 3 of its last 6 reports, yet the stock dropped in the first session after 2 of those 3 beats. The biggest move among the earlier reports followed the May 5, 2025 release, when EPS beat the estimate by 66.67% and the stock climbed 18.12%. For this fiscal year, analysts average an EPS estimate of -$0.5603, a fall of 209.9%, while their next-year figure is $0.4191.
HIMS typically moves 3.72% in a day, based on the 30-day standard deviation of its daily returns. The price sits 46.44% under its 52-week high of $52.41. Insiders sold $154.9M of stock over the last 18 months and bought $1.2M. Those sales may have been planned or made to cover taxes on vesting shares, so they carry less weight than open-market buying would.
HIMS against the Healthcare sector
How HIMS compares with the median Healthcare stock CleaRank tracks.
Price to sales vs sector: On price-to-sales, the yardstick used here in place of P/E, HIMS trades at 2.51x, -26% versus the sector average of 3.40x.
Return vs XLV: Since May 6, 2025, HIMS has lost 43.3% against a gain of 31.4% for XLV.
Performance against XLV
HIMS and the Healthcare sector fund over the same days.
Revenue and earnings
How much HIMS sells, and how much of it becomes profit.
Revenue growth: Revenue grew 59.0% in FY2025 to $2.3B, from $1.5B a year earlier.
Profit margin: The net margin was 5.5% in FY2025, down from 8.5% the year before.
Profitable: HIMS earned $128M in FY2025.
Earnings reality check
Did HIMS beat what analysts expected, and how did the stock react?
Earnings record: HIMS beat the analyst estimate in 3 of the last 6 quarters.
Market reaction: The stock fell in the first session after 2 of those 3 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Aug 10, 2026after close | -$0.05 | -$0.37 | -640.00% | -3.97% | -9.95% |
| Nov 3, 2025after close | $0.10 | $0.06 | -40.00% | -3.60% | -7.52% |
| Aug 4, 2025after close | $0.23 | $0.29 | +26.09% | -12.36% | -21.10% |
| May 5, 2025after close | $0.12 | $0.20 | +66.67% | +18.12% | +31.83% |
| Feb 24, 2025after close | $0.11 | $0.11 | +0.00% | -22.32% | -20.72% |
| Nov 4, 2024after close | $0.05 | $0.32 | +540.00% | -0.58% | +34.30% |
As of October 17, 2026, HIMS has beaten the analyst EPS estimate in 3 of its last 6 reported quarters and fell in the first trading session after 2 of those beats; its latest report, on August 10, 2026, came in 640.00% below the estimate and the stock moved -3.97% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
AI analysis and technicals
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
1/3RSI not overbought or oversold ›
The 14-day RSI is 45.8, in neutral territory.RSI above 50 ›
An RSI of 45.8 is below the 50 midpoint, so sellers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is negative, so the 12-day average is below the 26-day average.
CleaRank AI analysis of HIMS
The score, the reasoning behind it, and what could move the price next.
Hims & Hers Health, Inc. (HIMS) is caught between its two moving averages. The price, $28.07, sits 2.95% above the 200-day average of $27.27 but 4.27% below the 50-day average of $29.32. That 50-day average is 7.53% above the 200-day one, and the gap would tighten if the price keeps trading under the shorter average. Within its 52-week range, running from $13.74 to $52.41, the price stands at 37%.
Recent gains sit against a weaker longer record: the price rose 0.25% over the past month, fell 14.52% over the past three months and fell 52.54% over the past year. On momentum, the 14-day RSI reads 45.8, in the neutral zone, with the MACD line negative.
Rating reaffirmed ›
JP Morgan kept its Neutral rating on September 11, 2026.
Source: Analyst action, JP Morgan, September 11, 2026
Earnings miss ›
The August 10, 2026 report missed the EPS estimate by 640.00%, and the share price fell 3.97% in the first session after it.
Source: Earnings report, August 10, 2026
- The two closest levels frame the near term: the 20-day EMA at $29.14 sits above the price, and the 200-day SMA at $27.27 sits below it.
- The 14-day RSI is 45.8, which is neutral, and the MACD line is negative. Readings above 70 or below 30 would signal stretched momentum.
- The share price dropped 3.97% in the first session after the August 10, 2026 report. Over the last 6 reports, HIMS beat estimates in 3 of them.
HIMS sits above its 200-day average of $27.27 but under its 50-day average of $29.32, so the trend is mixed. Closing above the 50-day would flip both readings to upward, while closing below the 200-day would flip both to downward. For now, the price is wedged between the 200-day SMA ($27.27) below and the 20-day EMA ($29.14) above.
HIMS has a 14-day RSI of 45.8, which places it in neutral territory between 40 and 60.
Technical indicators
Momentum and trend for HIMS, from its daily closes.
As of October 17, 2026, with HIMS at $28.07, its 14-day RSI is 45.8 (neutral territory), its 50-day simple moving average is $29.32 and its 200-day is $27.27.
Calculated by CleaRank on daily closes as of October 17, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).
What HIMS moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 17, 2026, HIMS's 1-year correlation of daily returns is +0.38 with S&P 500 (SPY), +0.40 with Nasdaq 100 (QQQ), +0.30 with Bitcoin (BTC) and +0.11 with gold (XAU).
What Wall Street expects
The analysts' target range and how their ratings split.
Analysts checks
1/3Most analysts rate it a buy ›
3 of 15 analysts rate it a buy or strong buy, 12 a hold and 0 a sell.Median target above the price ›
The median 12-month target of $31.00 is 10.4% above the price.More buy ratings than three months ago ›
3 of 15 rate it a buy now, against 3 of 15 three months ago.
HIMS Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Sep 11, 2026 | JP Morgan | Assumes | Neutral |
| Aug 24, 2026 | Truist Securities | Maintains | Hold |
| Aug 21, 2026 | Barclays | Maintains | Overweight |
| Aug 11, 2026 | Citigroup | Maintains | Neutral |
| Aug 11, 2026 | Deutsche Bank | Maintains | Hold |
| Aug 11, 2026 | B of A Securities | Maintains | Neutral |
As of October 17, 2026, 15 Wall Street analysts cover HIMS: 3 rate it a buy or strong buy, 12 a hold and 0 a sell or strong sell. Their 12-month price targets range from $23.00 to $42.00, with a median of $31.00, 10.4% above the price of $28.07.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
A trade plan, if you want one
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
HIMS trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Entry Strategies pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
HIMS moves about 3.7% a day on average, so a stop can fill well past its level. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much HIMS tends to move, against the market and on its own.
The long record
HIMS's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
3/4Average daily move under 2% ›
The price has moved 3.72% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 86.0%, from February 2021 to May 2022, regained by June 2024.Most 1-year holds ended higher ›
65% of 1-year holding periods in the last 7 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in September 2019 is now worth $28,643, against $28,137 in the S&P 500 (SPY).
HIMS Drawdowns & Recovery
As of October 17, 2026, HIMS's worst peak-to-trough fall over the last 7 years with dividends reinvested was -86.0% (February 2021 to May 2022); it regained that peak by June 2024, 25 months after the low, and 65% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into HIMS in September 2019 is worth now, against the same amount in the S&P 500.
Against the market: HIMS beat the S&P 500 over this period: $28,643 against $28,137.
A $10,000 investment in HIMS in September 2019 would be worth about $28,643 today with dividends reinvested, compared with about $28,137 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to HIMS, and which have not.
Strongest month, May: an average of +19.79%, up in 4 of 7 years.
Weakest month, August: an average of -9.25%, up in 3 of 7 years.
This month, October: has averaged -1.86%, up in 1 of 7 years. Past seasonality does not repeat on schedule.
Over the last 7 years, HIMS's strongest calendar month has been May (average +19.79%, up in 4 of 7 years) and its weakest August (average -9.25%, up in 3 of 7 years).
Average return for each calendar month over the last 7 years, from weekly closing prices with dividends included.
Long-term scenarios
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in HIMS, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in HIMS today could grow to about $24,707 by 2036 in the base case, with a 90th-percentile outcome near $187,441 and a 10th-percentile outcome around $3,257. Projections are statistical simulations, not guarantees.
HIMS Stock Price Prediction: 2030
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $40.31 for HIMS by 2030 in the base case, from $28.07 today (1.4x over 4 years). The 10th-percentile path ends near $11.19. These are outcomes of a Monte Carlo simulation run on HIMS's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $16.19 | $30.73 | $58.32 | |
| 2028 | $13.59 | $33.64 | $83.25 | |
| 2029 | $12.14 | $36.82 | $112 | |
| 2030 | $11.19 | $40.31 | $145 | |
| 2031 | $10.53 | $44.12 | $185 |
Method: a lognormal simulation of HIMS's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles. HIMS is highly volatile, so its upside column reaches an extreme multiple; treat it as a statistical tail, not an expectation.
Insider trading
What the people running the company have bought and sold.
HIMS insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Insider buying: Insiders bought $1.2M on the open market and sold $154.9M.
As of October 17, 2026, HIMS insiders reported 90 open-market sales worth $154.9M and 1 open-market purchase worth $1.2M over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Sep 22, 2026 | Oluyemi Okupe
Chief Financial Officer
|
Sell | 29.3K | $876.8K |
| Sep 22, 2026 | Oluyemi Okupe
Chief Financial Officer
|
Option | 14.0K | $70.1K |
| Sep 16, 2026 | Soleil Boughton
Officer
|
Sell | 6.2K | $173.7K |
| Sep 15, 2026 | Michael Y Chi
Chief Operating Officer
|
Sell | 14.0K | $398.2K |
| Sep 15, 2026 | Mohamed Elshenawy
Chief Technology Officer
|
Sell | 8.0K | $225.8K |
| Sep 2, 2026 | Soleil Boughton
Officer
|
Sell | 3.5K | $98.0K |
| Aug 25, 2026 | Andrew Dudum
Chief Executive Officer
|
Grant | 463.3K | - |
| Aug 19, 2026 | Soleil Boughton
Officer
|
Sell | 25.1K | $691.8K |
| Aug 19, 2026 | Oluyemi Okupe
Chief Financial Officer
|
Sell | 4.9K | $148.1K |
| Aug 19, 2026 | Oluyemi Okupe
Chief Financial Officer
|
Option | 4.9K | $24.7K |
| Aug 18, 2026 | Deborah M Autor
Officer and Director
|
Sell | 16.8K | $467.1K |
| Aug 17, 2026 | Oluyemi Okupe
Chief Financial Officer
|
Sell | 64.8K | $2.2M |
| Aug 17, 2026 | Oluyemi Okupe
Chief Financial Officer
|
Option | 81.0K | $47.0K |
| Aug 14, 2026 | Deborah M Autor
Officer and Director
|
Grant | 32.9K | - |
| Aug 14, 2026 | Irene Becklund
Officer
|
Grant | 13.7K | - |
| Aug 14, 2026 | Soleil Boughton
Officer
|
Grant | 42.3K | - |
| Aug 14, 2026 | Patrick Harrison Carroll
Officer
|
Grant | 26.2K | - |
| Aug 14, 2026 | Michael Y Chi
Chief Operating Officer
|
Grant | 86.3K | - |
| Aug 14, 2026 | Andrew Dudum
Chief Executive Officer
|
Grant | 155.0K | - |
| Aug 14, 2026 | Mohamed Elshenawy
Chief Technology Officer
|
Grant | 188.3K | - |
| Aug 14, 2026 | Christopher D Payne
Director
|
Grant | 545 | - |
| Aug 14, 2026 | Kare Schultz
Director
|
Grant | 6.6K | - |
| Aug 14, 2026 | David B Wells
Director
|
Grant | 778 | - |
| Jul 17, 2026 | Oluyemi Okupe
Chief Financial Officer
|
Sell | 7.2K | $229.2K |
| Jul 17, 2026 | Oluyemi Okupe
Chief Financial Officer
|
Option | 7.2K | $35.9K |
| Jul 6, 2026 | Oluyemi Okupe
Chief Financial Officer
|
Sell | 7.2K | $261.4K |
| Jul 6, 2026 | Oluyemi Okupe
Chief Financial Officer
|
Option | 7.2K | $35.9K |
| Jun 22, 2026 | Oluyemi Okupe
Chief Financial Officer
|
Sell | 18.2K | $619.2K |
| Jun 22, 2026 | Oluyemi Okupe
Chief Financial Officer
|
Option | 6.4K | $31.9K |
| Jun 18, 2026 | Patrick Harrison Carroll
Officer
|
Sell | 23.7K | $830.4K |
| Jun 17, 2026 | Mohamed Elshenawy
Chief Technology Officer
|
Sell | 30.0K | $946.3K |
| Jun 17, 2026 | Michael Y Chi
Chief Operating Officer
|
Sell | 14.0K | $441.9K |
| Jun 17, 2026 | Irene Becklund
Officer
|
Sell | 12.1K | $370.5K |
| Jun 15, 2026 | Deborah M Autor
Officer and Director
|
Grant | 32.9K | - |
| Jun 15, 2026 | Irene Becklund
Officer
|
Grant | 16.0K | - |
| Jun 15, 2026 | Soleil Boughton
Officer
|
Grant | 42.3K | - |
| Jun 15, 2026 | Patrick Harrison Carroll
Officer
|
Grant | 25.9K | - |
| Jun 15, 2026 | Patrick Harrison Carroll
Officer
|
Grant | 4.1K | - |
| Jun 15, 2026 | Michael Y Chi
Chief Operating Officer
|
Grant | 86.3K | - |
| Jun 15, 2026 | Andrew Dudum
Chief Executive Officer
|
Grant | 155.0K | - |
| Jun 15, 2026 | Mohamed Elshenawy
Chief Technology Officer
|
Grant | 282.6K | - |
| Jun 15, 2026 | Anja L. Manuel
Director
|
Grant | 13.7K | - |
| Jun 15, 2026 | Oluyemi Okupe
Chief Financial Officer
|
Grant | 71.6K | - |
| Jun 15, 2026 | Christopher D Payne
Director
|
Grant | 14.3K | - |
| Jun 15, 2026 | David B Wells
Director
|
Grant | 4.6K | - |
| Jun 11, 2026 | Deborah M Autor
Officer and Director
|
Grant | 3.7K | - |
| Jun 11, 2026 | Delos M Cosgrove
Director
|
Grant | 3.7K | - |
| Jun 11, 2026 | Christiane Pendarvis
Director
|
Grant | 3.7K | - |
| Jun 11, 2026 | Garcia Andrea G Perez
Director
|
Grant | 3.7K | - |
| Jun 11, 2026 | Kare Schultz
Director
|
Grant | 3.7K | - |
| May 26, 2026 | David B Wells
Director
|
Buy | 48.4K | $1.2M |
| May 18, 2026 | Oluyemi Okupe
Chief Financial Officer
|
Sell | 8.0K | $187.9K |
| May 18, 2026 | Oluyemi Okupe
Chief Financial Officer
|
Option | 8.0K | $39.8K |
| Apr 20, 2026 | Oluyemi Okupe
Chief Financial Officer
|
Sell | 19.6K | $588.6K |
| Apr 20, 2026 | Soleil Boughton
Officer
|
Sell | 9.5K | $283.9K |
| Apr 20, 2026 | Oluyemi Okupe
Chief Financial Officer
|
Option | 12.6K | $108.5K |
| Apr 17, 2026 | Oluyemi Okupe
Chief Financial Officer
|
Sell | 54.9K | $1.5M |
| Apr 17, 2026 | Oluyemi Okupe
Chief Financial Officer
|
Option | 6.2K | $31.0K |
| Apr 9, 2026 | Andrew Dudum
Chief Executive Officer
|
Grant | 422.9K | - |
| Apr 6, 2026 | Oluyemi Okupe
Chief Financial Officer
|
Sell | 4.0K | $79.4K |
| Apr 6, 2026 | Oluyemi Okupe
Chief Financial Officer
|
Option | 4.0K | $19.9K |
| Mar 20, 2026 | Oluyemi Okupe
Chief Financial Officer
|
Sell | 9.2K | $219.1K |
| Mar 20, 2026 | Oluyemi Okupe
Chief Financial Officer
|
Option | 4.5K | $22.5K |
| Mar 17, 2026 | Michael Y Chi
Chief Operating Officer
|
Sell | 97.3K | $2.4M |
| Mar 17, 2026 | Irene Becklund
Officer
|
Sell | 5.5K | $136.5K |
| Mar 17, 2026 | Soleil Boughton
Officer
|
Sell | 4.8K | $118.8K |
| Mar 13, 2026 | Deborah M Autor
Officer and Director
|
Grant | 32.9K | - |
| Mar 13, 2026 | Irene Becklund
Officer
|
Grant | 18.0K | - |
| Mar 13, 2026 | Soleil Boughton
Officer
|
Grant | 41.4K | - |
| Mar 13, 2026 | Patrick Harrison Carroll
Officer and Director
|
Grant | 16.5K | - |
| Mar 13, 2026 | Michael Y Chi
Chief Operating Officer
|
Grant | 72.1K | - |
| Mar 13, 2026 | Andrew Dudum
Chief Executive Officer
|
Grant | 164.4K | - |
| Mar 13, 2026 | Oluyemi Okupe
Chief Financial Officer
|
Grant | 105.2K | - |
| Mar 13, 2026 | Christiane Pendarvis
Director
|
Grant | 15.2K | - |
| Feb 27, 2026 | Soleil Boughton
Officer
|
Sell | 4.7K | $70.7K |
| Feb 23, 2026 | Soleil Boughton
Officer
|
Grant | 273.8K | - |
| Feb 23, 2026 | Michael Y Chi
Chief Operating Officer
|
Grant | 365.1K | - |
| Feb 23, 2026 | Andrew Dudum
Chief Executive Officer
|
Grant | 794.0K | - |
| Feb 23, 2026 | Oluyemi Okupe
Chief Financial Officer
|
Grant | 410.7K | - |
| Feb 3, 2026 | Oluyemi Okupe
Chief Financial Officer
|
Sell | 5.3K | $139.1K |
| Feb 3, 2026 | Oluyemi Okupe
Chief Financial Officer
|
Option | 5.3K | $26.4K |
| Jan 20, 2026 | Oluyemi Okupe
Chief Financial Officer
|
Sell | 9.1K | $275.1K |
| Jan 20, 2026 | Oluyemi Okupe
Chief Financial Officer
|
Option | 9.1K | $56.8K |
| Jan 5, 2026 | Oluyemi Okupe
Chief Financial Officer
|
Sell | 9.1K | $306.5K |
| Jan 5, 2026 | Oluyemi Okupe
Chief Financial Officer
|
Option | 6.0K | $54.8K |
| Dec 22, 2025 | Oluyemi Okupe
Chief Financial Officer
|
Sell | 23.1K | $824.7K |
| Dec 17, 2025 | Michael Y Chi
Chief Operating Officer
|
Sell | 13.8K | $504.8K |
| Dec 17, 2025 | Patrick Harrison Carroll
Officer and Director
|
Sell | 10.0K | $367.9K |
| Dec 17, 2025 | Irene Becklund
Officer
|
Sell | 8.4K | $308.8K |
| Dec 17, 2025 | Deborah M Autor
Officer and Director
|
Sell | 7.1K | $259.0K |
| Dec 15, 2025 | Deborah M Autor
Officer and Director
|
Grant | 7.1K | - |
| Dec 15, 2025 | Irene Becklund
Officer
|
Grant | 18.0K | - |
| Dec 15, 2025 | Soleil Boughton
Officer
|
Grant | 41.4K | - |
| Dec 15, 2025 | Patrick Harrison Carroll
Officer and Director
|
Grant | 16.5K | - |
| Dec 15, 2025 | Michael Y Chi
Chief Operating Officer
|
Grant | 72.1K | - |
| Dec 15, 2025 | Andrew Dudum
Chief Executive Officer
|
Grant | 164.4K | - |
| Dec 15, 2025 | Oluyemi Okupe
Chief Financial Officer
|
Grant | 105.2K | - |
| Dec 9, 2025 | Garcia Andrea G Perez
Director
|
Sell | 2.5K | $97.9K |
| Dec 1, 2025 | Michael Y Chi
Chief Operating Officer
|
Grant | 5.0K | - |
| Nov 28, 2025 | Andrew Dudum
Chief Executive Officer
|
Grant | 1.1M | - |
| Nov 24, 2025 | Soleil Boughton
Officer
|
Sell | 2.6K | $92.7K |
| Nov 17, 2025 | Oluyemi Okupe
Chief Financial Officer
|
Sell | 23.2K | $853.5K |
| Nov 17, 2025 | Oluyemi Okupe
Chief Financial Officer
|
Option | 23.2K | $165.8K |
| Nov 12, 2025 | Andrew Dudum
Chief Executive Officer
|
Grant | 3.3M | - |
| Nov 10, 2025 | Soleil Boughton
Officer
|
Sell | 2.6K | $112.2K |
| Oct 27, 2025 | Soleil Boughton
Officer
|
Sell | 2.6K | $132.1K |
| Oct 17, 2025 | Oluyemi Okupe
Chief Financial Officer
|
Sell | 11.6K | $662.2K |
| Oct 17, 2025 | Oluyemi Okupe
Chief Financial Officer
|
Option | 11.6K | $82.9K |
| Oct 16, 2025 | Andrew Dudum
Chief Executive Officer
|
Sell | 175.7K | $11.0M |
| Oct 16, 2025 | Andrew Dudum
Chief Executive Officer
|
Option | 125.3K | $304.6K |
| Oct 13, 2025 | Soleil Boughton
Officer
|
Sell | 2.6K | $143.4K |
| Oct 10, 2025 | Michael Y Chi
Officer
|
Sell | 900 | $52.4K |
| Oct 10, 2025 | Michael Y Chi
Officer
|
Option | 900 | $6.1K |
| Oct 3, 2025 | Oluyemi Okupe
Chief Financial Officer
|
Sell | 11.6K | $669.2K |
| Oct 3, 2025 | Oluyemi Okupe
Chief Financial Officer
|
Option | 11.6K | $82.9K |
| Oct 1, 2025 | Michael Y Chi
Officer
|
Sell | 250 | $14.0K |
| Oct 1, 2025 | Michael Y Chi
Officer
|
Option | 250 | $2.9K |
| Sep 29, 2025 | Oluyemi Okupe
Chief Financial Officer
|
Sell | 85.0K | $5.1M |
| Sep 29, 2025 | Soleil Boughton
Officer
|
Sell | 2.6K | $155.0K |
| Sep 29, 2025 | Oluyemi Okupe
Chief Financial Officer
|
Option | 49.8K | $249.7K |
Source: TwelveData, from SEC Form 4 filings
Questions people ask
Answered from the figures on this page, as of October 17, 2026.